MYELOPEROXIDASE AND COENZYME Q10 MODULATED IN THE CHRONIC KIDNEY DISEASE PATIENTS

Kidney failure, also known as end-stage kidney disease, is a medical condition in which the kidneys are functioning at less than 15% of normal. Kidney failure is classified as either acute kidney failure, which develops rapidly and may resolve; and chronic kidney failure, which develops slowly. Diagnosis of chronic failure is based on a glomerular filtration rate (GFR) of less than 15 or the need for renal replacement therapy. It is also equivalent to stage 5 chronic kidney disease.The study aimed to evaluate the role of MPO and Co Q10 in different stages of CKD, and correlates this parameter with urea, Cr, Na, K, and eGFR.A Case-control study is carried out in Baghdad in the Imamian Kadhimian Medical City and Al-Karamah Teaching Hospital between August 2022 and March 2023. The number of CKD males under study were 60 male whose ages were between 25 to 50 years old. In addition, the control group consisted of 30 healthy volunteer males aged between 25 to 50 years and they did not have any diseases. Blood samples were collected from each male for measurement of Myeloperoxidase (MPO), and Coenzyme Q10 by Enzyme-linked immunosorbent assay (ELISA). The study showed that the reduced mean level of myeloperoxidase (p<0.001) in the patient's group compared with the control group, (19.9±6.82 ng/ml) and (42.4±4.98 ng/ml) respectively. Our study revealed that with increasing CKD stage, the myeloperoxidase levels decrease. Also, the reduced mean level of Coenzyme Q10 was 2.97±0.511 ng/ml in the patient group was highly significant than the control group's 7.07±2.41 ng/ml (p<0.001). Our study revealed that with increasing CKD stage, the coenzyme Q10 levels decrease. The study found a positive correlation of serum myeloperoxidase with coenzyme Q10 in CKD patients.